

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/5B60B8662EFEN.html>

Date: July 2018

Pages: 55

Price: US\$ 3,500.00 (Single User License)

ID: 5B60B8662EFEN

Abstracts

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2018

SUMMARY

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) pipeline Target constitutes close to 17 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report 5' Nucleotidase - Pipeline Review, H2 2018, outlays comprehensive information on the 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - 5'-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5'nucleotides. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 5 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Solid Tumor, Bladder Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Kidney Cancer (Renal Cell Cancer), Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Non-Small Cell Lung Carcinoma, Peritoneal Cancer, Renal Cell Carcinoma, Sarcomas and Uterine Cancer.

Furthermore, this report also reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

The report reviews 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics and enlists all their major and minor projects

The report assesses 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Overview

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Companies

Involved in Therapeutics Development

Arcus Biosciences Inc

Bristol-Myers Squibb Co

Corvus Pharmaceuticals Inc

Evotec AG

Innate Pharma SA

InteRNA Technologies BV

MedImmune LLC

Novartis AG

Peloton Therapeutics Inc

Selvita SA

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Drug Profiles

AB-680 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986179 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPX-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-1B3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IPH-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oleclumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-2828 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules Inhibits CD39 and CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ADORA2A and CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CD73 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRF-373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Dormant Products

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Product Development Milestones

Featured News & Press Releases

Jun 12, 2018: Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930

Apr 26, 2018: Corvus Pharmaceuticals Announces Initiation of Phase 1/1b Clinical Trial of Investigational Anti-CD73 Antibody, CPI-006, in Patients with Advanced Cancer

Apr 18, 2018: InterRNA Demonstrates Preclinical Proof-of-Concept for Lead microRNA Candidate INT-1B3 in a Range of Cancer Models at 2018 AACR Annual Meeting

Mar 15, 2018: Arcus Biosciences to Present Data on Oncology Product Candidate AB680 at AACR 2018 Annual Meeting

Dec 19, 2016: Surface Oncology Announces Collaboration with Dr. John Stagg, a World-Leader in the Adenosine Pathway

Apr 18, 2016: Innate Pharma presents new CD73 checkpoint inhibitor program

Feb 24, 2014: CD73 Research Could Lead to Cancer Drug

Appendix

Methodology

Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Arcus Biosciences Inc, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Corvus Pharmaceuticals Inc, H2 2018
Pipeline by Evotec AG, H2 2018
Pipeline by Innate Pharma SA, H2 2018
Pipeline by InterRNA Technologies BV, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by Peloton Therapeutics Inc, H2 2018
Pipeline by Selvita SA, H2 2018
Dormant Projects, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Arcus Biosciences Inc

Bristol-Myers Squibb Co

Corvus Pharmaceuticals Inc

Evotec AG

Innate Pharma SA

InteRNA Technologies BV

MedImmune LLC

Novartis AG

Peloton Therapeutics Inc

Selvita SA

I would like to order

Product name: 5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/5B60B8662EFEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/5B60B8662EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

